A hypothesis-generating pharmacologic profile that proposes repurposing sargramostim (GM‑CSF) for PD by outlining immunomodulatory and potential neuroprotective mechanisms but provides no new primary data.

Although lacking primary results, the paper highlights a concrete, repurposable therapeutic (sargramostim) that targets neuroinflammation and regulatory T‑cell pathways, offering translational rationale and trial-ready hypotheses for biomarker-driven interventional studies.